Plain-English translation of NCT04777084 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two medications — and lenvatinib — to treat advanced non-small cell lung cancer. The trial has three groups based on your cancer history and genetic markers. Researchers want to see if this medication combination can help people whose cancer has continued to grow despite previous treatments.
Some people with advanced lung cancer stop responding to earlier treatments. This trial exists to find out whether combining this medication with another drug might work better for patients whose cancer has become resistant to standard therapies.
You likely qualify if…
You likely don't qualify if…
You will receive the two medications together by injection or infusion, continuing until your cancer progresses, side effects become too severe, or you choose to stop. You will have imaging scans (like CT scans) every 6 weeks for the first 24 weeks, then every 8 weeks after that, so doctors can monitor how your cancer is responding. The study continues until it's clear the medication is no longer helping or you experience unmanageable side effects.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
China